ACM
TERN icon

ADAR1 Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

ADAR1 Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-914,699
Closed -$48.2M – 341
2026
Q1 		$48.2M Buy
914,699
+373,084
+69% +$15.3M 2.84% 6
2025
Q4 		$21.9M Buy
541,615
+531,615
+5,316% +$12.3M 1.61% 12
2025
Q3 		$75.1K Sell
10,000
-18,415
-65% -$118K 0.01% 204
2025
Q2 		$106K Buy
+28,415
New +$88.7K 0.02% 174
2024
Q4 		– Sell
-24,702
Closed -$206K – 296
2024
Q3 		$206K Buy
24,702
+9,702
+65% +$79.8K 0.03% 162
2024
Q2 		$102K Buy
15,000
+10,000
+200% +$60.6K 0.02% 165
2024
Q1 		$32.8K Sell
5,000
-8,007
-62% -$52.3K 0.01% 204
2023
Q4 		$84.4K Buy
+13,007
New +$68.8K 0.03% 100

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADAR1 Capital Management's TERN Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 914,699 shares — an estimated $48.2M sold.

ADAR1 Capital Management first reported a position in TERN in Q4 2023 and held it in 8 quarters. The position peaked at $48.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 914,699 Terns Pharmaceuticals shares in Q2 2026, an estimated $48.2M.
  • ADAR1 Capital Management first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • ADAR1 Capital Management's Terns Pharmaceuticals position peaked at $48.2M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.